belantamab mafodotin (Blenrep)

following a full submission assessed under the orphan equivalent medicine process:

belantamab mafodotin (Blenrep®) is accepted for restricted use within NHSScotland.

Indication under review: in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

SMC restriction: Patients with relapsed or refractory multiple myeloma eligible for second line treatment for whom lenalidomide is an unsuitable treatment option.

In an open-label phase III study in patients with relapsed or refractory multiple myeloma after at least one prior line of therapy, belantamab mafodotin in combination with bortezomib plus dexamethasone was associated with statistically significant improvements in progression-free survival compared with an anti-CD38 monoclonal antibody in combination with a proteasome inhibitor and a glucocorticoid.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.